|
Gene: OTUD6B |
Gene summary for OTUD6B |
Gene summary. |
Gene information | Species | Human | Gene symbol | OTUD6B | Gene ID | 51633 |
Gene name | OTU deubiquitinase 6B | |
Gene Alias | CGI-77 | |
Cytomap | 8q21.3 | |
Gene Type | protein-coding | GO ID | GO:0006464 | UniProtAcc | Q8N6M0 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51633 | OTUD6B | LZE24T | Human | Esophagus | ESCC | 5.25e-08 | 1.62e-01 | 0.0596 |
51633 | OTUD6B | P2T-E | Human | Esophagus | ESCC | 1.35e-04 | 1.13e-01 | 0.1177 |
51633 | OTUD6B | P4T-E | Human | Esophagus | ESCC | 5.77e-04 | 1.60e-01 | 0.1323 |
51633 | OTUD6B | P5T-E | Human | Esophagus | ESCC | 2.09e-08 | 1.88e-01 | 0.1327 |
51633 | OTUD6B | P8T-E | Human | Esophagus | ESCC | 8.74e-04 | 6.69e-02 | 0.0889 |
51633 | OTUD6B | P9T-E | Human | Esophagus | ESCC | 1.53e-02 | 7.12e-02 | 0.1131 |
51633 | OTUD6B | P10T-E | Human | Esophagus | ESCC | 2.32e-08 | 2.03e-01 | 0.116 |
51633 | OTUD6B | P11T-E | Human | Esophagus | ESCC | 3.00e-05 | 2.43e-01 | 0.1426 |
51633 | OTUD6B | P12T-E | Human | Esophagus | ESCC | 2.13e-15 | 2.48e-01 | 0.1122 |
51633 | OTUD6B | P15T-E | Human | Esophagus | ESCC | 2.74e-09 | 1.04e-01 | 0.1149 |
51633 | OTUD6B | P16T-E | Human | Esophagus | ESCC | 1.16e-14 | 3.21e-01 | 0.1153 |
51633 | OTUD6B | P20T-E | Human | Esophagus | ESCC | 1.46e-06 | 1.59e-01 | 0.1124 |
51633 | OTUD6B | P21T-E | Human | Esophagus | ESCC | 2.26e-09 | 2.71e-01 | 0.1617 |
51633 | OTUD6B | P22T-E | Human | Esophagus | ESCC | 5.19e-12 | 1.28e-01 | 0.1236 |
51633 | OTUD6B | P23T-E | Human | Esophagus | ESCC | 6.05e-14 | 3.57e-01 | 0.108 |
51633 | OTUD6B | P24T-E | Human | Esophagus | ESCC | 7.89e-05 | 1.19e-01 | 0.1287 |
51633 | OTUD6B | P26T-E | Human | Esophagus | ESCC | 2.39e-08 | 1.81e-01 | 0.1276 |
51633 | OTUD6B | P27T-E | Human | Esophagus | ESCC | 2.54e-06 | 1.71e-01 | 0.1055 |
51633 | OTUD6B | P28T-E | Human | Esophagus | ESCC | 3.74e-14 | 2.16e-01 | 0.1149 |
51633 | OTUD6B | P30T-E | Human | Esophagus | ESCC | 7.50e-09 | 3.78e-01 | 0.137 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | |
Breast | IDC | |
Breast | DCIS | |
Cervix | CC | |
Cervix | HSIL_HPV |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:007064612 | Esophagus | ESCC | protein modification by small protein removal | 95/8552 | 157/18723 | 1.25e-04 | 8.56e-04 | 95 |
GO:004324811 | Esophagus | ESCC | proteasome assembly | 11/8552 | 12/18723 | 1.26e-03 | 6.06e-03 | 11 |
GO:00165793 | Esophagus | ESCC | protein deubiquitination | 79/8552 | 139/18723 | 5.23e-03 | 1.97e-02 | 79 |
GO:00432481 | Liver | HCC | proteasome assembly | 12/7958 | 12/18723 | 3.46e-05 | 3.45e-04 | 12 |
GO:00706461 | Liver | HCC | protein modification by small protein removal | 91/7958 | 157/18723 | 6.50e-05 | 5.92e-04 | 91 |
GO:00165791 | Liver | HCC | protein deubiquitination | 78/7958 | 139/18723 | 8.13e-04 | 4.87e-03 | 78 |
GO:00432482 | Oral cavity | OSCC | proteasome assembly | 11/7305 | 12/18723 | 2.45e-04 | 1.57e-03 | 11 |
GO:00706462 | Oral cavity | OSCC | protein modification by small protein removal | 77/7305 | 157/18723 | 6.55e-03 | 2.43e-02 | 77 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OTUD6B | SNV | Missense_Mutation | novel | c.14N>G | p.Val5Gly | p.V5G | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.603) | TCGA-C8-A273-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | |
OTUD6B | SNV | Missense_Mutation | c.37N>T | p.Pro13Ser | p.P13S | protein_coding | tolerated_low_confidence(0.54) | benign(0) | TCGA-E9-A1NC-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR | ||
OTUD6B | insertion | Frame_Shift_Ins | novel | c.854_855insAAATGGACTGCTT | p.Glu286AsnfsTer5 | p.E286Nfs*5 | protein_coding | TCGA-B6-A0IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |||
OTUD6B | SNV | Missense_Mutation | novel | c.662N>C | p.Val221Ala | p.V221A | protein_coding | tolerated(0.4) | benign(0) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
OTUD6B | SNV | Missense_Mutation | rs539885905 | c.708N>A | p.Met236Ile | p.M236I | protein_coding | tolerated(0.26) | benign(0.005) | TCGA-AD-6964-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | folfox | PD | |
OTUD6B | SNV | Missense_Mutation | c.68N>A | p.Arg23His | p.R23H | protein_coding | tolerated_low_confidence(0.67) | benign(0.001) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
OTUD6B | SNV | Missense_Mutation | novel | c.543N>T | p.Gln181His | p.Q181H | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
OTUD6B | SNV | Missense_Mutation | c.88N>C | p.Val30Leu | p.V30L | protein_coding | tolerated_low_confidence(0.06) | benign(0.053) | TCGA-F5-6813-01 | Colorectum | rectum adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD | ||
OTUD6B | SNV | Missense_Mutation | c.929N>T | p.Ser310Leu | p.S310L | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | ||
OTUD6B | deletion | Frame_Shift_Del | rs762934606 | c.867delN | p.Lys291AsnfsTer3 | p.K291Nfs*3 | protein_coding | TCGA-AA-3833-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |